EDIT
Price
$3.15
Change
-$0.11 (-3.37%)
Updated
Jul 25 closing price
Capitalization
263.7M
3 days until earnings call
PRME
Price
$4.21
Change
-$0.14 (-3.22%)
Updated
Jul 25 closing price
Capitalization
566.23M
10 days until earnings call
Interact to see
Advertisement

EDIT vs PRME

Header iconEDIT vs PRME Comparison
Open Charts EDIT vs PRMEBanner chart's image
Editas Medicine
Price$3.15
Change-$0.11 (-3.37%)
Volume$1.28M
Capitalization263.7M
Prime Medicine
Price$4.21
Change-$0.14 (-3.22%)
Volume$2.17M
Capitalization566.23M
EDIT vs PRME Comparison Chart in %
Loading...
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EDIT vs. PRME commentary
Jul 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EDIT is a Hold and PRME is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 27, 2025
Stock price -- (EDIT: $3.15 vs. PRME: $4.21)
Brand notoriety: EDIT and PRME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EDIT: 47% vs. PRME: 54%
Market capitalization -- EDIT: $263.7M vs. PRME: $566.23M
EDIT [@Biotechnology] is valued at $263.7M. PRME’s [@Biotechnology] market capitalization is $566.23M. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EDIT’s FA Score shows that 0 FA rating(s) are green whilePRME’s FA Score has 0 green FA rating(s).

  • EDIT’s FA Score: 0 green, 5 red.
  • PRME’s FA Score: 0 green, 5 red.
According to our system of comparison, EDIT is a better buy in the long-term than PRME.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EDIT’s TA Score shows that 4 TA indicator(s) are bullish while PRME’s TA Score has 2 bullish TA indicator(s).

  • EDIT’s TA Score: 4 bullish, 4 bearish.
  • PRME’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, EDIT is a better buy in the short-term than PRME.

Price Growth

EDIT (@Biotechnology) experienced а +14.13% price change this week, while PRME (@Biotechnology) price change was +1.94% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.60%. For the same industry, the average monthly price growth was +17.32%, and the average quarterly price growth was +27.29%.

Reported Earning Dates

EDIT is expected to report earnings on Jul 30, 2025.

PRME is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+7.60% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PRME($566M) has a higher market cap than EDIT($264M). EDIT YTD gains are higher at: 148.032 vs. PRME (44.178). PRME has higher annual earnings (EBITDA): -200M vs. EDIT (-244.52M). EDIT has more cash in the bank: 221M vs. PRME (144M). EDIT has less debt than PRME: EDIT (31.1M) vs PRME (121M). EDIT has higher revenues than PRME: EDIT (35.8M) vs PRME (3.85M).
EDITPRMEEDIT / PRME
Capitalization264M566M47%
EBITDA-244.52M-200M122%
Gain YTD148.03244.178335%
P/E RatioN/AN/A-
Revenue35.8M3.85M931%
Total Cash221M144M153%
Total Debt31.1M121M26%
FUNDAMENTALS RATINGS
EDIT vs PRME: Fundamental Ratings
EDIT
PRME
OUTLOOK RATING
1..100
8888
VALUATION
overvalued / fair valued / undervalued
1..100
43
Fair valued
60
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9998
PRICE GROWTH RATING
1..100
3635
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EDIT's Valuation (43) in the Biotechnology industry is in the same range as PRME (60) in the null industry. This means that EDIT’s stock grew similarly to PRME’s over the last 12 months.

EDIT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as PRME (100) in the null industry. This means that EDIT’s stock grew similarly to PRME’s over the last 12 months.

PRME's SMR Rating (98) in the null industry is in the same range as EDIT (99) in the Biotechnology industry. This means that PRME’s stock grew similarly to EDIT’s over the last 12 months.

PRME's Price Growth Rating (35) in the null industry is in the same range as EDIT (36) in the Biotechnology industry. This means that PRME’s stock grew similarly to EDIT’s over the last 12 months.

PRME's P/E Growth Rating (100) in the null industry is in the same range as EDIT (100) in the Biotechnology industry. This means that PRME’s stock grew similarly to EDIT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EDITPRME
RSI
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
88%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
86%
Momentum
ODDS (%)
N/A
Bearish Trend 3 days ago
88%
MACD
ODDS (%)
Bullish Trend 3 days ago
80%
Bearish Trend 3 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
75%
Advances
ODDS (%)
Bullish Trend 5 days ago
77%
Bullish Trend 7 days ago
78%
Declines
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
IMIMF0.07N/A
+7.45%
Copper Quest Expl Inc
ASHTF69.000.82
+1.21%
Ashtead Group PLC
HUGPF46.36N/A
N/A
Hugo Boss AG
KWHAF0.24N/A
N/A
K. Wah International Holdings Ltd.
MNNGF0.08N/A
N/A
Affluent Partners Holdings Ltd.

EDIT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EDIT has been loosely correlated with CRSP. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if EDIT jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EDIT
1D Price
Change %
EDIT100%
-3.37%
CRSP - EDIT
53%
Loosely correlated
-1.97%
NTLA - EDIT
49%
Loosely correlated
+6.38%
RXRX - EDIT
48%
Loosely correlated
+3.67%
PRME - EDIT
47%
Loosely correlated
-3.22%
SLDB - EDIT
47%
Loosely correlated
+4.79%
More

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with CRSP. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
-3.22%
CRSP - PRME
58%
Loosely correlated
-1.97%
RXRX - PRME
55%
Loosely correlated
+3.67%
BEAM - PRME
54%
Loosely correlated
+3.68%
CRBU - PRME
49%
Loosely correlated
-3.80%
CCCC - PRME
48%
Loosely correlated
-1.31%
More